Ranbaxy a good stock to be kept in portfolio: Ajay Srivastava

In a chat with ET Now, Ajay Srivastava, CEO, Dimensions Consulting shares his views on Ranbaxy:

ET Now: What are your thoughts on Ranbaxy?

Ajay Srivastava: It is a good stock to be in but Japanese parents have never been good parents or companies on the listed side that is a honest fact because I do not think they have grip with the situation. Every good performance over quarter is balanced by the next quarter. If you look at the last quarter results of Ranbaxy every alternate or every third quarter they have one very bad news filtering in perhaps market is feeling that the end of the bad news has happened so now it will start to move with the rest of the industry that is one alternative.

The question is should you buy the stock and keep it in a portfolio we have it in our portfolio, the answer is yes, because it got a very good domestic product, it has got very good consumer products. We all heard about Revital and Moov etc. so there is a good portfolio consumer products, pharma products, Indian market is doing well.